Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: implications for clinical practice and future investigations

Critical Care

Brittany K. Bankhead-Kendall¹  Marvin G. Chang²  Adam Flaczyk³  Edward A. Bittner³  Rachel P. Rosovsky⁴  Clay T. Reed⁵ 

[1] Department of Surgery, Division of Trauma, Emergency Surgery, and Surgical Critical Care, Massachusetts General Hospital, Boston, MA, USA;Division of Cardiac Anesthesia and Critical Care, Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, USA;Division of Critical Care, Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, USA;Division of Hematology and Oncology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, USA;Division of Hematology and Oncology, National Institutes of Health, Bethesda, MD, USA;

关键词: COVID-19;    Coronavirus;    Thrombosis;    Anticoagulation;    Venous thromboembolism;    Hematologic monitoring;    Therapeutic anticoagulation;   

DOI  :  10.1186/s13054-020-03273-y

来源: Springer

【 摘 要 】

Critically ill patients with COVID-19 are at increased risk for thrombotic complications which has led to an intense debate surrounding their anticoagulation management. In the absence of data from randomized controlled clinical trials, a number of consensus guidelines and recommendations have been published to facilitate clinical decision-making on this issue. However, substantive differences exist between these guidelines which can be difficult for clinicians. This review briefly summarizes the major societal guidelines and compares their similarities and differences. A common theme in all of the recommendations is to take an individualized approach to patient management and a call for prospective randomized clinical trials to address important anticoagulation issues in this population.

【 授权许可】

CC BY